Dr. Miles Chen
Manager
Golden Biotechnology Corporation, Taiwan
Taiwan
Biography
Miles is General Manager at Golden Biotechnology Corporation, Taiwan. In this role, he is responsible for the discovery and selection of new drugs for development and the overall strategic planning of GBC`s business. In this position, he exerted himself to understand the MoA of a natural small molecule named Antroquinonol. Antroquinonol is a NME with demonstrated anti-cancer, liver protection, immune-modulatory, and anti-inflammatory effects. Phase I trial showed low toxicity profile with no treatment-related deaths and serious adverse events among NSCLC patients refractory to conventional treatments. Antroquinonol has been granted Orphan Drug Status by the FDA and European Commission for the treatment of pancreatic cancer, AML, and HCC. Its postulated mechanism of action for isoprenyltransferase inhibitor in turn blocks the necessary post-translational modifications of RAS and RAS-related proteins responsible for cancer cell proliferation. The Nrf2 activator and NF-ï«B inhibitor roles of Antroquinonol were also be demonstrated in vivo. Miles graduated with a PhD in Graduate Institute of Biotechnology from National Chung Hsing University Taiwan, and completed his postdoctoral research at the Academia Sinica Taiwan.
Research Interest
He exerted himself to understand the MoA of a natural small molecule named Antroquinonol.